for October 2018
NEW @PharmacoJournal by @amylcarr Clinical Utility of MRSA Nasal Screening for Antimicrobial Stewardship: A Review of Current Literature. https://t.co/jSjROnNH7M pic.twitter.com/9YdUbVHfjJ
— Antibiotic Steward (@ABsteward) October 11, 2018
New in CID By @BBookstaver_USC
— Antibiotic Steward (@ABsteward) October 12, 2018
Role of Early De-escalation of Antimicrobial Therapy on Risk of Clostridioides difficile Infection following Enterobacteriaceae Bloodstream Infections https://t.co/MSYJapPfOG pic.twitter.com/M4lJlRuZie
NEW 🔥in OFID by @JGPharmD/@SIDPharm /@ClaeysKcclaeys /@Bruce_M_Jones
— Antibiotic Steward (@ABsteward) October 31, 2018
Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: A multicenter study https://t.co/iy6j3fwLHT pic.twitter.com/ZVtNdNogda
Will increasing fluid intake help prevent UTI 🤔.
— Antibiotic Steward (@ABsteward) October 1, 2018
A NEW 🔥randomized clinical trial @JAMAInternalMed confirms that! Women who consumed additional water had approximately 50% reduction in number of cystitis episodes&were prescribed fewer antibiotics. https://t.co/Qh40tcI85b pic.twitter.com/71W4L5EWHz
Breaking news 📢📢 US FDA has approved NUZYRA™ (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). #IDWeek2018 @accpinfdprn @SIDPharm @IDstewardshiphttps://t.co/yeke0zVZgQ
— Antibiotic Steward (@ABsteward) October 3, 2018
We are up to about 100,000 children under age 2 in the United States who have not been vaccinated against 14 infectious diseases — and rising. https://t.co/Zlh2ucvGSj
— Atul Gawande (@Atul_Gawande) October 12, 2018
Happy birthday to the great Antonie!
— ASM (@ASMicrobiology) October 24, 2018
Who first observed animalcules wee
His new microscope
Gave scientists hope
To see bacteria, viruses, and fungi#sciencelimerick
Learn more about van Leeuwenhoek and his Dutch surroundings: https://t.co/Y38bphc9Z9 pic.twitter.com/E41HNacDns
JUST Published 🔥🔥 TANGO II RCT by @Keith_S_Kaye in @InfectDis_Ther
— Antibiotic Steward (@ABsteward) October 1, 2018
Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The Randomized Clinical Trial #vabomere https://t.co/nKtS5NAuQx pic.twitter.com/uRWJElKo3e
“The world is facing an antibiotic apocalypse.” Scientists warn of the international spread of antimicrobial resistance and the life threatening consequences that it poses. #AMR @guardian https://t.co/wRqCti29hM
— IDSA (@IDSAInfo) October 27, 2018
A NEW🔥Review article Dr.Pranita D.Tamma & @emilylheil
— Antibiotic Steward (@ABsteward) October 29, 2018
The Antibiotic Arms Race: Current and Emerging Therapy for KPC- Producing Bacteria. https://t.co/xkElpZ9OmM pic.twitter.com/XiL5h8Q6bA
Great new article about key #AntimicrobialStewardship program resources; recommends a physician:pharmacist FTE ratio of 1:3 & indicates that prospective audit & feedback should be ASP cornerstone: https://t.co/hovhPblqC1 @IDSAInfo
— Mike Stevens (@Dr_Mike_Stevens) October 15, 2018
Shorter is Smarter! ⏳ Short courses of antibiotics can provide similar efficacy with less harm for residents of long-term care homes.
— Brad Langford (@BRxAD) October 18, 2018
New resources available: https://t.co/mrd4Zob9aa#ShorterisSmarter #ASPChat #AntimicrobialStewardship @allan_k_grillMD @BradSpellberg pic.twitter.com/PKHkCsdp10
NEW Review article @@ASMicrobiology @Burcu__Isler /@davidantibiotic
— Antibiotic Steward (@ABsteward) October 15, 2018
New Treatment Options Against Carbapenem-Resistant Acinetobacter baumannii Infectionshttps://t.co/4iQ4bFxwX6 pic.twitter.com/gGHpB1iIK4
Want help keeping up with ID/stewardship publications?
— Antibiotic Steward (@ABsteward) October 6, 2018
We have got your back! Here are our monthly picks for the top new journal articles trending on Twitter. I'm so proud to collaborate with @IDstewardship. #medtwitter #foamed https://t.co/Q72JxLsNpy
Just Published 🔥in CID
— Antibiotic Steward (@ABsteward) October 3, 2018
New avenues for antimicrobial stewardship: the case for penicillin skin testing by pharmacists. #IDWeek2018 #IDupdates https://t.co/CjsQKg9qHN pic.twitter.com/YtXVcoX5o5
NEW🔥 Meta-analysis published in CID Patients with bacteremia receiving PCT-guided antibiotic management demonstrates lower antibiotic exposure without an apparent increase in mortality. https://t.co/xcV5IZ7QoA pic.twitter.com/JOOs5NUzX4
— Antibiotic Steward (@ABsteward) October 25, 2018
⭐️ New! September is over, did you miss anything? Here is a 📄 journal article rundown from @ABsteward & I 📲 https://t.co/SPOACRuQKq ...For more 🔥 hot stuff in ID/stewardship this week watch #IDweek2018 + #SIDP2018
— Tim Gauthier (@IDstewardship) October 3, 2018
cc: @hboucher3 @MerinoTrial @BryanMogle @e_charani @ACCP pic.twitter.com/eXMVIwsJgg
How long does it take for your gut bacteria to recover after antibiotics?
— Microbes&Infection (@MicrobesInfect) October 26, 2018
A study found most gut microbed returned to normal within ~1.5 months after taking antibiotics, but several common, beneficial, bacteria were still missing up to 6 months later.https://t.co/5AitkVf1my pic.twitter.com/aG6sd3oEsK
Infections by multidrug-resistant Gram-negative Bacteria: what's new in our arsenal and what's in the pipeline? A NEW Review article by @padstamundo and Prof Jeff Lipman. https://t.co/2ahNS5xr1H pic.twitter.com/Xg9wz43WRQ
— Antibiotic Steward (@ABsteward) October 27, 2018
Our grip on infectious diseases is slipping as people turn away from vaccination. https://t.co/9K8bsXOeJV
— Popular Science (@PopSci) October 23, 2018
Analysis of the clinical antibacterial and antituberculosis pipeline. NEW review article in @TheLancetInfDis Great work by @ThwaitesGuy et Al Highly recommended for all #antibioticstewards and #idprn https://t.co/9yKMGQDVTw pic.twitter.com/xSyNSOLa69
— Antibiotic Steward (@ABsteward) October 16, 2018
Happy to have this paper finally out!
— Michael Ison (@MichaelIsonMD) October 9, 2018
Early oseltamivir after hospital admission is associated with shortened hospitalization: A five-year analysis of oseltamivir timing and clinical outcomes | Clinical Infectious Diseases | Oxford Academic https://t.co/6FA1G5pyuM
Detecting diseases from bacteria is one thing. Picking up the presence of viruses is trickier https://t.co/L5jVN0X43w
— The Economist (@TheEconomist) October 21, 2018
It's getting easier and easier to Tx bacteremia orally. And later and later for late adopters to continue to refuse. Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study https://t.co/you3rtxh4B
— Brad Spellberg (@BradSpellberg) October 24, 2018
If you're wondering about that new single-dose flu drug, baloxavir (Xofluza), here are a few thoughts. And yes, it's going to cost more than oseltamivir. Latest post: https://t.co/GQgqD3gSg9
— Paul Sax (@PaulSaxMD) October 29, 2018
⬇️ Therapeutic efficacy in pts with Renal impairment 🤔
— Antibiotic Steward (@ABsteward) October 8, 2018
A NEW🔥article @PharmacoJournal by Dr.Lodise:Suboptimal Clinical Response Rates with Newer Antibiotics in Patients w Moderate Renal Impairment:Review of the Literature&Potential PK/PD Considerations https://t.co/uiIzeIasJt pic.twitter.com/nFRGY3SfFp
NEW 🔥🔥RCT Just published in @TheLancetInfDis
— Antibiotic Steward (@ABsteward) October 26, 2018
IV infusion of Cefiderocol (2 gQ8h) was non-inferior compared with Imipenem-cilastatin (1 g Q8h) for the treatment of cUTI in people with MDR(arbapenem resistant Excluded) infections. Via @jeffpears0n. https://t.co/FW7opoeCfx pic.twitter.com/SFmuzRrCzE
@PHE_uk #ESPAUR report will be available at 00.15 23rd October. https://t.co/R2D6cDu1vT Find out the latest data on #antibiotic use, resistance #amr and #stewardship intervention #antibioticguardian pic.twitter.com/lsHq0GXMy5
— Susan Hopkins (@SMHopkins) October 22, 2018
Breaking news 📢📢
— Antibiotic Steward (@ABsteward) October 7, 2018
Finally :EMA committee(PRAC) recommends restrictions on fluoroquinolone, quinolone antibiotics. Thanks @LightfootFair for sharing. #IDWeek2018
Cc:@AntibioticLeedshttps://t.co/wqaJMvnSCb pic.twitter.com/WjIHdAel1n
Overdiagnosis of Penicillin Allergy Leads to Costly, Inappropriate Treatment | Allergy and Clinical Immunology | JAMA | JAMA Network https://t.co/aP3oRMEQ95
— Eric Macy (@EricMacyMD) October 27, 2018
Proud RPD moment...congrats Brian Buss, @EmilySpivak, and team! Impact of a Multiplex PCR Assay for Bloodstream Infections with and without Antimicrobial Stewardship Intervention at a Cancer Hospital | Open Forum Infectious Diseases | Oxford Academic https://t.co/LbVgwrdg3p
— Russell Benefield (@Russellmonas) October 12, 2018
Today we launch a report looking at how vaccines can be utilised to address drug-resistant infections. With @BCG we have examined how vaccines can reduce the impact of antibiotic resistant pathogens, read the report here https://t.co/GwlVaI8FMN#VaccinesWork to #StopSuperbugs pic.twitter.com/jmABVGKXBw
— AMR at Wellcome (@Wellcome_AMR) October 5, 2018
NEW 🔥 propensity-matched cohort 🇪🇸 study just published in CID: Early oral switch to linezolid for low-risk patients with SAB from day 3 to 9 of treatment until completion yielded similar clinical outcomes & allow earlier discharge. https://t.co/6yANLHirI9 pic.twitter.com/peqYO5sTa6
— Antibiotic Steward (@ABsteward) October 23, 2018
'#AntimicrobialResistance needs to be a top 5 policy priority - that's the conclusion of the Health & Social Care Select Committee, published today in its report on AMR' #StopSuperbugs https://t.co/MuWKCXXsqS via @UKParliament
— Antibiotic Action (@TheUrgentNeed) October 22, 2018
Scary stuff: New route of acquiring #antibiotic resistance in bacteria is the most potent one to date https://t.co/ArMfHCINKl
— Battle Superbugs (@battlesuperbugs) October 13, 2018
Meet the trillions of viruses that make up your #virome
— Microbes&Infection (@MicrobesInfect) October 21, 2018
Every surface of our body - inside and out - is covered in microorganisms: bacteria, viruses, fungi and many other microscopic life forms.https://t.co/3RT0GFQBOW #microbiome #microbiota
👏🏼👏🏼👏🏼 @S_BouAntoun @AHolmesID @HPRUamr @PHE_uk assessment of potential unintended consequences following a national antimicrobial stewardship programme in England: an interrupted time analysis https://t.co/tKKRyxq7ll
— Esmita Charani (@e_charani) October 18, 2018
Register to find out more about the new Grant Scheme: Commonwealth Partnerships for Antimicrobial Stewardship #CwPAMS. https://t.co/uphuSzEpK3. All pharmacy teams can get involved/lead cc @FlemingFund @THETlinks @CW_Pharmacists pic.twitter.com/whOw1gCpXK
— Diane Ashiru, PhD (@DrDianeAshiru) October 17, 2018
NEW in @accpchest
— Antibiotic Steward (@ABsteward) October 27, 2018
Outcomes associated with de-escalating anti-MRSA therapy in culture-negative nosocomial pneumonia. Patients who were not de-escalated received 5 more days of MRSA coverage&had a higher incidence of AKI than patients who were de-escalatedhttps://t.co/yyBIIEpZQZ pic.twitter.com/WzZqRXGmuL
Weekend downloads of e-Book on Antimicrobial Stewardship were by colleagues in Brazil, UK, Spain, Portugal, Iran, US, Algeria, Italy and India - impressive global engagement! DONT MISS OUT- free copy now! https://t.co/Mz5g3oSwTp … … … … … pic.twitter.com/GuCqEXbbQ9
— Antibiotic Action (@TheUrgentNeed) October 15, 2018
Reporting #AntimicrobialResistance in animals. Sustained reduction #antibiotics and well worth reading + great #dataviz https://t.co/RStyW3g0t4 pic.twitter.com/fchOQIOHkR
— Elizabeth Beech (@elizbeech) October 24, 2018
NEW 🔥 in @PharmacoJournal Omadacycline Enters the Ring: A New Antimicrobial Contender.
— Antibiotic Steward (@ABsteward) October 5, 2018
A new review article by @stoverkr/ @jwagsIDPharmDhttps://t.co/wkyAGvMTrq#IDWeek2018 #Nuzyra pic.twitter.com/vpX918tMgZ
A minireview on β-lactamases, which have driven research in academic laboratories since the early 1940s #AACJournal https://t.co/9MOIS6qhxW pic.twitter.com/3hT2ZTB98w
— ASM (@ASMicrobiology) October 3, 2018
Preoperative oral antibiotic prophylaxis with tobramycin& colistin prior to colorectal surgery is associated with a significant ⬇️ in SSI and/or mortality in a setting without MBP: NEW study 🇳🇱
— Antibiotic Steward (@ABsteward) October 3, 2018
published in CID. Quiet shocking Colistin😲 #IDWeek2018 https://t.co/RwRZQLkKEu pic.twitter.com/rMVZlUeRU6
You know that weird #MelaniaEdwards piece in @businessinsider? Here's the academic medicine version, with thanks to @SaxCarolyn for content and h/t to @AllisonRBond @ml_barnett. Latest post:https://t.co/VlfjxebxXW
— Paul Sax (@PaulSaxMD) October 21, 2018
Hot off the ASM Press! "Antimicrobial Resistance in Bacteria from Livestock and Companion Animals" is a comprehensive resource detailing how the global spread of #antimicrobial-resistant pathogenic bacteria is a continuing challenge for humans and animals. https://t.co/ytGrmaMA2V pic.twitter.com/rXHCws8A6P
— ASM (@ASMicrobiology) October 7, 2018
Researchers Find Correlation between Showerhead #Bacteria and Lung Infections - New Study in @ASMicrobiology's @mbiojournal https://t.co/g2mxgHjMrX pic.twitter.com/t54GYaG8Lg
— ASM Newsroom (@ASMnewsroom) October 30, 2018
It's the bacteria not the person that becomes resistant to antibiotics!
— Fran Kerr (@Frankerr1F) October 11, 2018
How will you get the #AntibioticResistance
Message out for World Antibiotic Awareness Week#WAAW 12-18th Nov 2018
Join up to be an #antibioticguardian today! https://t.co/4Rw07B8lCd pic.twitter.com/n9FPl1R1JC
The British Association of Oral Surgeons @BAOS_UK has launched a new Antimicrobial Stewardship e-Learning resource for oral health professionals to test their knowledge of antibiotic prescribing: https://t.co/GzkBvH7esT@FGDP_UK
— Dr Sandra White (@DentalPHE) October 31, 2018
🤓 Another great article in JCM. This type of information can be hard to understand in terms of practical clinical significance, but it’s super important towards antimicrobial stewarship efforts. #BadBugsNeedDrugs
— Tim Gauthier (@IDstewardship) October 25, 2018
📄👉🏼 https://t.co/zezieRqbXB
cc: @ASMicrobiology @JClinMicro pic.twitter.com/kmgi8S9Rbf
NEW : Very interesting study from 🇧🇷 : Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem. @BSACandJAC https://t.co/c4pUJODkrN pic.twitter.com/k6REu4IrOC
— Antibiotic Steward (@ABsteward) October 30, 2018
Created by Cameron Forbes. Last updated November 10, 2019 at 15:41 EST.